Eid Joseph 4

What Happened Joseph Eid, Executive Vice President, R&D and Chief Medical Officer of Geron Corp (GERN), received a grant of 2,220,000 derivative shares (an equity award) on February 17, 2026. The award was reported at $0.00 per share (derivative grant), so no cash was exchanged at grant. This is a compensation/retention award rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-02-17; filing date: 2026-02-19 (reported two days after the transaction).
• Instrument: Derivative award — 2,220,000 shares granted at $0.00 per share.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnote: The award vests in 48 equal monthly installments beginning March 17, 2026, contingent on continuous service (see footnote F1).
• No 10b5-1 plan, tax withholding, or sale reported in this filing.

Context This was an equity grant (common for executive compensation) that will vest monthly over four years; it does not represent an immediate market purchase or sale. Because the shares vest over time and are contingent on continued service, this is typically seen as compensation/retention rather than a direct signal of immediate insider buying or selling.